Systemic treatment with the inhibitory neurotransmitter gamma-aminobutyric acid aggravates experimental autoimmune encephalomyelitis by affecting proinflammatory immune responses

Journal of Neuroimmunology

Volumn 255, Issue 1-2, 2013, Pages 45-53

  Carmans, Sofie ^a   Hendriks, Jerome J A ^a   Slaets, Helena ^a   Thewissen, Kristof ^a   Stinissen, Piet ^a   Rigo, Jean Michel ^a   Hellings, Niels ^a  

^a HASSELT UNIVERSITY   (Belgium)

Author keywords

Experimental autoimmune encephalomyelitis; Gamma amino butyric acid; Multiple sclerosis; Vigabatrin, macrophage, T cell

Indexed keywords

4 AMINOBUTYRIC ACID; INTERLEUKIN 6; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; STAT3 PROTEIN; TUMOR NECROSIS FACTOR ALPHA; VIGABATRIN;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DISEASE EXACERBATION; DISEASE SEVERITY; FEMALE; IMMUNE RESPONSE; IN VIVO STUDY; LYMPHOCYTE PROLIFERATION; MOUSE; NEUROPROTECTION; NONHUMAN; PERITONEUM MACROPHAGE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; TH1 CELL;

ANIMALS; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; GABA AGENTS; GAMMA-AMINOBUTYRIC ACID; INFLAMMATION; MICE; MICE, INBRED C57BL; MULTIPLE SCLEROSIS; NEURAL INHIBITION; NEUROIMMUNOMODULATION; SEVERITY OF ILLNESS INDEX;

EID: 84872672897     PISSN: 01655728     EISSN: 18728421     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2012.11.001     Document Type: Article

References (68)

1. Achar V.S., Welch K.M., Chabi E., Bartosh K., Meyer J.S. Cerebrospinal fluid gamma-aminobutyric acid in neurologic disease. Neurology 1976, 26:777-780.
2. Alam S., Laughton D.L., Walding A., Wolstenholme A.J. Human peripheral blood mononuclear cells express GABAA receptor subunits. Mol. Immunol. 2006, 43:1432-1442.
3. Balamanyam N.V., Katz L., Hare T.A., Gerber J.C., Grossman M.H. Levels of gamma-aminobutyric acid in cerebrospinal-fluid in various neurologic disorders. Arch. Neurol. 1980, 37:352-355.
4. Bhat R., Axtell R., Mitra A., Miranda M., Lock C., Tsien R.W., Steinman L. Inhibitory role for GABA in autoimmune inflammation. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:2580-2585.
5. Bibolini M.J., Chanaday N.L., Báez N.S., Degano A.L., Monferran C.G., Roth G.A. Inhibitory role of diazepam on autoimmune inflammation in rats with experimental autoimmune encephalomyelitis. Neuroscience 2011, 199:421-428.
6. Bjurstrom H., Wang J., Ericsson I., Bengtsson M., Liu Y., Kurnar-Mendu S., Issazadeh-Navikas S., Birnir B. GABA, a natural immunomodulator of T lymphocytes. J. Neuroimmunol. 2008, 205:44-50.
7. Campbell I.L., Abraham C.R., Masliah E., Kemper P., Inglis J.D., Oldstone M.B.A., Mucke L. Neurologic disease induced in transgenic mice by cerebral overexpression of interleukin-6. Proc. Natl. Acad. Sci. U. S. A. 1993, 90:10061-10065.
8. Costa C., Leone G., Saulle E., Pisani F., Bernardi G., Calabresi P. Coactivation of GABA(A) and GABA(B) receptor results in neuroprotection during in vitro ischemia. Stroke 2004, 35:596-600.
9. Cox G.W., Melillo G., Chattopadhyay U., Mullet D., Fertel R.H., Varesio L. Tumor necrosis factor-alpha-dependent production of reactive nitrogen intermediates mediates Ifn-gamma plus Il-2-induced murine macrophage tumoricidal activity. J. Immunol. 1992, 149:3290-3296.
10. Demakova E.V., Korobov V.P., Lemkina L.M. Determination of gamma-aminobutyric acid concentration and activity of glutamate decarboxylase in blood serum of patients with multiple sclerosis. Klin. Lab. Diagn. 2003, 15-17.
11. Duthey B., Hubner A., Diehl S., Boehncke S., Pfeffer J., Boehncke W.H. Anti-inflammatory effects of the GABA(B) receptor agonist baclofen in allergic contact dermatitis. Exp. Dermatol. 2010, 19:661-666.
12. Dutta R., Trapp B.D. Pathogenesis of axonal and neuronal damage in multiple sclerosis. Neurology 2007, 68:S22-S31.
13. Enna S.J., Stern L.Z., Wastek G.J., Yamamura H.I. Cerebrospinal fluid gamma-aminobutyric acid variations in neurological disorders. Arch. Neurol. 1977, 34:683-685.
14. Erdo S.L., Wolff J.R. Gamma-aminobutyric acid outside the mammalian brain. J. Neurochem. 1990, 54:363-372.
15. Gold B.I., Bowers M.B., Roth R.H., Sweeney D.W. GABA levels in CSF of patients with psychiatric disorders. Am. J. Psychiatry 1980, 137:362-364.
16. Gordon S. Alternative activation of macrophages. Nat. Rev. Immunol. 2003, 3:23-35.
17. Gottesfeld Z., Teitelbaum D., Webb C., Arnon R. Changes in the GABA system in experimental allergic encephalomyelitis-induced paralysis. J. Neurochem. 1976, 27:695-699.
18. Halonen T., Miettinen R., Toppinen A., Tuunanen J., Kotti T., Riekkinen P.J. Vigabatrin protects against kainic acid-induced neuronal damage in the rat hippocampus. Neurosci. Lett. 1995, 195:13-16.
19. Han M.H., Hwang S.I., Roy D.B., Lundgren D.H., Price J.V., Ousman S.S., Fernald G.H., Gerlitz B., Robinson W.H., Baranzini S.E., Grinnell B.W., Raine C.S., Sobel R.A., Han D.K., Steinman L. Proteomic analysis of active multiple sclerosis lesions reveals therapeutic targets. Nature 2008, 451:1076-1081.
20. Hempel L., Korholz D., Bonig H., Schneider M., Kleinvehne A., Packeisen J., Mauzkorholz C., Burdach S. Interleukin-10 directly inhibits the interleukin-6 production in T-cells. Scand. J. Immunol. 1995, 41:462-466.
21. Hendriks J.J.A., Slaets H., Carmans S., de Vries H.E., Dijkstra C.D., Stinissen P., Hellings N. Leukemia inhibitory factor modulates production of inflammatory mediators and myelin phagocytosis by macrophages. J. Neuroimmunol. 2008, 204:52-57.
22. Honegger C.G., Krenger W., Langemann H. Changes in amino-acid contents in the spinal cord and brain stem of rats with experimental autoimmune encephalomyelitis. J. Neurochem. 1989, 53:423-427.
23. Israf D.A., Tham C.L., Syahida A., Lajis N.H., Sulaiman M.R., Mohamad A.S., Zakaria Z.A. Atrovirinone inhibits proinflammatory mediator synthesis through disruption of NF-kappa B nuclear translocation and MAPK phosphorylation in the murine monocytic macrophage RAW 264.7. Phytomedicine 2010, 17:732-739.
24. Jee Y., Kim G., Tanuma N., Matsumoto Y. STAT expression and localization in the central nervous system during autoimmune encephalomyelitis in Lewis rats. J. Neuroimmunol. 2001, 114:40-47.
25. Jin Z., Mendu S.K., Birnir B. GABA is an effective immunomodulatory molecule. Amino Acids 2011, 41:1193-1197.
26. Kalviainen R., Halonen T., Pitkanen A., Riekkinen P.J. Amino-acid levels in the cerebrospinal-fluid of newly diagnosed epileptic patients - effect of vigabatrin and carbamazepine monotherapies. J. Neurochem. 1993, 60:1244-1250.
27. Kang J., Jiang L., Goldman S.A., Nedergaard M. Astrocyte-mediated potentiation of inhibitory synaptic transmission. Nat. Neurosci. 1998, 1:683-692.
28. Klueva J., Meis S., de Lima A.D., Voigt T., Munsch T. Developmental downregulation of GABAergic drive parallels formation of functional synapses in cultured mouse neocortical networks. Dev. Neurobiol. 2008, 68:934-949.
29. Krnjevic K. Role of GABA in cerebral cortex. Can. J. Physiol. Pharmacol. 1997, 75:439-451.
30. Kuhn S.A., van Landeghem F.K., Zacharias R., Farber K., Rappert A., Pavlovic S., Hoffmann A., Nolte C., Kettenmann H. Microglia express GABA(B) receptors to modulate interleukin release. Mol. Cell. Neurosci. 2004, 25:312-322.
31. Kuriyama K., Sze P.Y. Blood-brain barrier to H-3-gamma-aminobutyric acid in normal and amino oxyacetic acid-treated animals. Neuropharmacology 1971, 10:103-108.
32. Langer D.H., Brown G.L., Bunney W.E., van Kammen D.P. Letter: gamma-aminobutyric acid in CSF in schizophrenia. N. Engl. J. Med. 1975, 293:201.
33. Lee N., Neitzel K.L., Devlin B.K., MacLennan A.J. STAT3 phosphorylation in injured axons before sensory and motor neuron nuclei: potential role for STAT3 as a retrograde signaling transcription factor. J. Comp. Neurol. 2004, 474:535-545.
34. Liu X.B., Lee Y.S., Yu C.R., Egwuagu C.E. Loss of STAT3 in CD4(+) T cells prevents development of experimental autoimmune diseases. J. Immunol. 2008, 180:6070-6076.
35. Lock C., Hermans G., Pedotti R., Brendolan A., Schadt E., Garren H., Langer-Gould A., Strober S., Cannella B., Allard J., Klonowski P., Austin A., Lad N., Kaminski N., Galli S.J., Oksenberg J.R., Raine C.S., Heller R., Steinman L. Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nat. Med. 2002, 8:500-508.
36. Mansfield P.J., Shayman J.A., Boxer L.A. Regulation of polymorphonuclear leukocyte phagocytosis by myosin light chain kinase after activation of mitogen-activated protein kinase. Blood 2000, 95:2407-2412.
37. Martin R., McFarland H.F., Mcfarlin D.E. Immunological aspects of demyelinating diseases. Annu. Rev. Immunol. 1992, 10:153-187.
38. Martinez F.O., Sica A., Mantovani A., Locati M. Macrophage activation and polarization. Front. Biosci. 2008, 13:453-461.
39. Mendu S.K., Akesson L., Jin Z., Edlund A., Cilio C., Lernmark A., Birnir B. Increased GABA(A) channel subunits expression in CD8(+) but not in CD4(+) T cells in BB rats developing diabetes compared to their congenic littermates. Mol. Immunol. 2011, 48:399-407.
40. Merrill J.E., Kono D.H., Clayton J., Ando D.G., Hinton D.R., Hofman F.M. Inflammatory leukocytes and cytokines in the peptide-induced disease of experimental allergic encephalomyelitis in Sjl and B10.Pl mice. Proc. Natl. Acad. Sci. U. S. A. 1992, 89:574-578.
41. Mosmann T.R., Coffman R.L. Heterogeneity of cytokine secretion patterns and functions of helper T-cells. Adv. Immunol. 1989, 46:111-147.
42. Narumi S., Finke J.H., Hamilton T.A. Interferon-gamma and interleukin-2 synergize to induce selective monokine expression in murine peritoneal macrophages. J. Biol. Chem. 1990, 265:7036-7041.
43. Navikas V., Link H. Review: cytokines and the pathogenesis of multiple sclerosis. J. Neurosci. Res. 1996, 45:322-333.
44. Okuda Y., Sakoda S., Bernard C.C.A., Fujimura H., Saeki Y., Kishimoto T., Yanagihara T. IL-6-deficient mice are resistant to the induction of experimental autoimmune encephalomyelitis provoked by myelin oligodendrocyte glycoprotein. Int. Immunol. 1998, 10:703-708.
45. Petroff O.A.C., Rothman D.L., Behar K.L., Collins T.L., Mattson R.H. Human brain GABA levels rise rapidly after initiation of vigabatrin therapy. Neurology 1996, 47:1567-1571.
46. Pitt D., Werner P., Raine C.S. Glutamate excitotoxicity in a model of multiple sclerosis. Nat. Med. 2000, 6:67-70.
47. Qasimi P., Ming-Lum A., Ghanipour A., Ong C.J., Cox M.E., Ihle J., Cacalano N., Yoshimura A., Mui A.L.F. Divergent mechanisms utilized by SOCS3 to mediate interleukin-10 inhibition of tumor necrosis factor alpha and nitric oxide production by macrophages. J. Biol. Chem. 2006, 281:6316-6324.
48. Rane M.J., Gozal D., Butt W., Gozal E., Pierce W.M., Guo S.Z., Wu R., Goldbart A.D., Thongboonkerd V., McLeish K.R., Klein J.B. Gamma-amino butyric acid type B receptors stimulate neutrophil chemotaxis during ischemia-reperfusion. J. Immunol. 2005, 174:7242-7249.
49. Reyes-Garcia M.G., Hernandez-Hernandez F., Hernandez-Tellez B., Garcia-Tamayo F. GABA (A) receptor subunits RNA expression in mice peritoneal macrophages modulate their IL-6/IL-12 production. J. Neuroimmunol. 2007, 188:64-68.
50. Samavati L., Rastogi R., Du W.J., Huettemann M., Fite A., Franchi L. STAT3 tyrosine phosphorylation is critical for interleukin 1 beta and interleukin-6 production in response to lipopolysaccharide and live bacteria. Mol. Immunol. 2009, 46:1867-1877.
51. Schousboe A., Larsson O.M., Seiler N. Stereoselective uptake of the gaba-transaminase inhibitors gamma-vinyl gaba and gamma-acetylenic gaba into neurons and astrocytes. Neurochem. Res. 1986, 11:1497-1505.
52. Schweizer U., Gunnersen J., Karch C., Wiese S., Holtmann B., Tekada K., Akira S., Sendtner M. Conditional gene ablation of Stat3 reveals differential signaling requirements for survival of motoneurons during development and after nerve injury in the adult. J. Cell Biol. 2002, 156:287-297.
53. Sills G.J., Butler E., Thompson G.G., Brodie M.J. Vigabatrin and tiagabine are pharmacologically different drugs. A pre-clinical study. Seizure Eur. J. Epilepsy 1999, 8:404-411.
54. Simpson R.J., Hammacher A., Smith D.K., Matthews J.M., Ward L.D. Interleukin-6: structure-function relationships. Protein Sci. 1997, 6:929-955.
55. Stangel M. Neuroprotection and neuroregeneration in multiple sclerosis. J. Neurol. 2008, 255:77-81.
56. Tajouri L., Mellick A.S., Ashton K.J., Tannenberg A.E., Nagra R.M., Tourtellotte W.W., Griffiths L.R. Quantitative and qualitative changes in gene expression patterns characterize the activity of plaques in multiple sclerosis. Brain Res. Mol. Brain Res. 2003, 119:170-183.
57. Tian J., Chau C., Hales T.G., Kaufman D.L. GABA(A) receptors mediate inhibition of T cell responses. J. Neuroimmunol. 1999, 96:21-28.
58. Tian J.D., Lu Y.X., Zhang H.W., Chau C.H., Dang H.N., Kaufman D.L. gamma-aminobutyric acid inhibits T cell autoimmunity and the development of inflammatory responses in a mouse type 1 diabetes model. J. Immunol. 2004, 173:5298-5304.
59. Tian J., Dang H., Kaufman D.L. Combining antigen-based therapy with GABA treatment synergistically prolongs survival of transplanted ß-cells in diabetic NOD mice. PLoS One 2011, 6:e25337.
60. Tian J., Dang H.N., Yong J., Chui W.S., Dizon M.P., Yaw C.K., Kaufman D.L. Oral treatment with gamma-aminobutyric acid improves glucose tolerance and insulin sensitivity by inhibiting inflammation in high fat diet-fed mice. PLoS One 2011, 6:e25338.
61. Traugott U., Reinherz E.L., Raine C.S. Multiple-sclerosis - distribution of T-cell subsets within active chronic lesions. Science 1983, 219:308-310.
62. VandenPol A.N., Obrietan K., Chen G. Excitatory actions of GABA after neuronal trauma. J. Neurosci. 1996, 16:4283-4292.
63. Vanheel A., Daniels R., Plaisance S., Baeten K., Hendriks J.J., Leprince P., Dumont D., Robben J., BrÔne B., Stinissen P., Noben J.P., Hellings N. Identification of protein networks involved in the disease course of experimental autoimmune encephalomyelitis, an animal model of multiple sclerosis. PLoS One 2012, 7:e35544.
64. Wang Y., Feng D.C., Liu G.X., Luo Q.Q., Xu Y., Lin S.T., Fei J., Xu L.Y. Gamma-aminobutyric acid transporter 1 negatively regulates T cell-mediated immune responses and ameliorates autoimmune inflammation in the CNS. J. Immunol. 2008, 181:8226-8236.
65. Watanabe M., Maemura K., Kanbara K., Tamayama T., Hayasaki H. GABA and GABA receptors in the central nervous system and other organs. Int. Rev. Cytol. 2002, 213:1-47.
66. Weinstein S.L., Sanghera J.S., Lemke K., Defranco A.L., Pelech S.L. Bacterial lipopolysaccharide induces tyrosine phosphorylation and activation of mitogen-activated protein kinases in macrophages. J. Biol. Chem. 1992, 267:14955-14962.
67. Wood J.H., Hare T.A., Glaeser B.S., Ballenger J.C., Post R.M. Low cerebrospinal fluid gamma-aminobutyric acid content in seizure patients. Neurology 1979, 29:1203-1208.
68. Ziegler M.G., Brooks B.R., Lake C.R., Wood J.H., Enna S.J. Norepinephrine and gamma-aminobutyric acid in amyotrophic lateral sclerosis. Neurology 1980, 30:98-101.